Allergy Therapy by Intranasal Administration with Recombinant Lactococcus lactis Producing Bovine beta-Lactoglobulin

作者：Cortes Perez Naima G; Ah Leung Sandrine; Bermudez Humaran Luis G; Corthier Gerard; Langella Philippe; Wal Jean Michel; Adel Patient Karine^*

来源：International Archives of Allergy and Immunology, 2009, 150(1): 25-31.

DOI：10.1159/000210377

• Allergy therapy
• beta-Lactoglobulin
• Th1/Th2 balance
• Lactococcus lactis

Background: In the last years, the use of probiotics such as lactic acid bacteria (LAB) has been proposed as an attractive alternative for the management of allergic diseases. A partial prevention from sensitization to bovine beta-lactoglobulin (BLG), one of the major cows' milk allergens, could be achieved in mice after intranasal administration with a recombinant LAB strain, Lactococcus lactis, producing BLG (LL-BLG). This study aimed to evaluate the effects of the LL-BLG strain in a therapeutic protocol. Methods: Three groups of mice were first orally sensitized to cows' milk and then intranasally administered with either the LL-BLG strain, BLG protein alone or saline solution. Serum samples were collected to analyze BLG-specific IgE, IgG1 and IgG2a, and mice were further intranasally challenged with BLG to elicit a specific allergic reaction. Results: Treatment with LL-BLG, but not with BLG alone, contributed to diminish IgG1 production in serum and bronchoalveolar lavage fluids. This was associated with decreased IL-4 production and enhanced IFN-gamma production by BLG-reactivated splenocytes, suggesting a switch from Th2- to Th1-immune response. Furthermore, we observed that administration of LL-BLG or LL locally reduced the allergic reaction induced after intranasal challenge, as evidenced by decreased release of IL-4 in bronchoalveolar lavage fluids. Conclusion: These preliminary results demonstrate the efficiency of the intranasal administration of LL-BLG for specific therapy against cows' milk-related allergy.

• 出版日期2009
• 单位中国地震局